SCHEMBL20134846

SCHEMBL20134846

CC(C)(C)OC(=O)N1CCC(n2cc3cc(Cl)ccc3n2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.47
STS P08842 3/20 0.46
GPR119 Q8TDV5 2/20 0.46
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
USP2 O75604 1/20 0.44
HPGD P15428 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
NR3C1 P04150 2/20 0.44
HCAR1 Q9BXC0 1/20 0.43
CNR2 P34972 1/20 0.43
CACNB4 O00305 2/20 0.42
CACNA1A O00555 2/20 0.42
CACNA1G O43497 2/20 0.42
CACNG3 O60359 2/20 0.42
CACNA1F O60840 2/20 0.42
CACNA1H O95180 2/20 0.42
CACNB3 P54284 2/20 0.42
CACNA2D1 P54289 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135633 0.87 FPR2 (0.45) GPR119HCAR1MAPT
SCHEMBL17109250 0.86 KMT2A (0.44) GPR119MEN1KMT2AHPGDHSD17B10
SCHEMBL20135591 0.84 GPR119 (0.50) GPR119HCAR1
SCHEMBL25198469 0.84 MET (0.43) STSGPR119NR3C1HCAR1MAPT
SCHEMBL25198478 0.83 HCAR1 (0.44) CNR1STSGPR119NR3C1HCAR1
SCHEMBL17092710 0.82 GPR119 (0.47) GPR119MEN1KMT2AHPGDNPSR1
SCHEMBL29042019 0.81 USP30 (0.47) GPR119HCAR1
SCHEMBL29042052 0.81 USP30 (0.47) GPR119HCAR1
SCHEMBL25210991 0.80 USP30 (0.46) GPR119HCAR1MAPT
SCHEMBL25338952 0.80 NR1H2 (0.46) GPR119HCAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 CNR1 2194/4885STS 1401/4885GPR119 799/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 CNR1 2870/4885STS 1402/4885GPR119 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.